Table 1.
Patient Characteristics
| Demographic | Participants (N=18) |
|---|---|
| Age (years) | 59.8 ± 14.7 |
| Male/Female | 7 (39) / 11 (61) |
| BMI (kg/m2) | 31.9 ± 7.1 |
| Smoking status | |
| Never smoker | 10 (56) |
| Ex-smoker | 8 (44) |
| Blood eosinophils (x109/L) | 0.1 (IQR 0.0–0.2) |
| Serum immunoglobulin E (IU/mL) | 29.5 (IQR 9–299) |
| Asthma biologic at time of 1st BT session* | |
| None | 13 (72) |
| Mepolizumab | 3 (17) |
| Benralizumab | 2 (11) |
Notes: Values are presented as mean ± standard deviation, median (IQR) or number (%). *Some patients in this study underwent bronchial thermoplasty prior to the availability of mepolizumab, benralizumab and dupilumab in Australia.